Modelling the prevalence and cost of back pain with neuropathic components in the general population

被引:74
作者
Schmidt, Carsten O. [1 ]
Schweikert, Bernd [2 ,3 ,4 ]
Wenig, Christina M. [2 ,3 ,4 ]
Schmidt, Uwe [5 ]
Gockel, Ulrich [6 ]
Freynhagen, Rainer [7 ]
Toelle, Thomas R. [8 ]
Baron, Ralf [9 ]
Kohlmann, Thomas [1 ]
机构
[1] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, D-17475 Greifswald, Germany
[2] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management, Neuherberg, Germany
[3] Univ Munich, Munich Sch Management, Inst Hlth Econ & Hlth Care Management, Munich, Germany
[4] Munich Ctr Hlth Sci, Munich, Germany
[5] StatConsult GmbH, Magdeburg, Germany
[6] Pfizer Pharma GmbH, Karlsruhe, Germany
[7] Univ Klinikum Dusseldorf, Anasthesiol Klin, Dusseldorf, Germany
[8] Tech Univ Munich, Neurol Klin, Munich, Germany
[9] Univ Kiel, Kiel, Germany
关键词
Low back pain; Neuropathic pain; Cost of illness; General population; VALIDATION; QUESTIONNAIRE; BURDEN; EPIDEMIOLOGY; DISORDERS; DIAGNOSIS; ORIGIN; SCALE;
D O I
10.1016/j.ejpain.2008.12.003
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Background: Although there is increasing knowledge of the prevalence of neuropathic pain, little has been done to isolate the cost of neuropathic pain, especially with reference to the frequent complaint of back pain. Aims: To estimate the prevalence of neuropathic components in back pain and associated costs. Methods: We used available epidemiological data to model the prevalence of neuropathic back pain in the general adult population, combining three studies: painDETECT 1, painDETECT 2, and the German back pain research network (GBPRN) study, representing a total of 21,047 subjects. The painDETECT screening questionnaire was used in the former two surveys to assess neuropathic pain components. Costing data were obtained from 1718 participants in the GBPRN survey. Results: According to our model, approximately 4% of the general adult population experienced back pain with a neuropathic component. Owing to the greater severity of neuropathic pain, its costs were found to be disproportionately high: among patients with persistent back pain, typical costs associated with a person suffering neuropathic back pain were higher than those of an average back pain patient, and as much as 67% higher than those of a patient with nociceptive back pain only. Approximately, 16% of the total costs associated with back pain were attributable to pain with a neuropathic component. Conclusions: Back pain with neuropathic components is likely to affect a relevant proportion of the general adult population and cause a disproportionately high share of back pain-related costs. (C) 2009 Published by Elsevier Ltd. on behalf of European Federation of International Association for the Study of Pain Chapters.
引用
收藏
页码:1030 / 1035
页数:6
相关论文
共 36 条
[1]
The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs [J].
Bennett, M .
PAIN, 2001, 92 (1-2) :147-157
[2]
The S-LANSS score for identifying pain of predominantly neuropathic origin: Validation for use in clinical and postal research [J].
Bennett, MI ;
Smith, BH ;
Torrance, N ;
Potter, J .
JOURNAL OF PAIN, 2005, 6 (03) :149-158
[3]
Using screening tools to identify neuropathic pain [J].
Bennett, Michael I. ;
Attal, Nadine ;
Backonja, Miroslav M. ;
Baron, Ralf ;
Bouhassira, Didier ;
Freynhagen, Rainer ;
Scholz, Joachim ;
Toelle, Thomas R. ;
Wittchen, Hans-Ulrich ;
Jensen, Troels Staehelin .
PAIN, 2007, 127 (03) :199-203
[4]
Clinical characteristics and economic costs of patients with painful neuropathic disorders [J].
Berger, A ;
Dukes, EM ;
Oster, G .
JOURNAL OF PAIN, 2004, 5 (03) :143-149
[5]
Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) [J].
Bouhassira, D ;
Attal, N ;
Alchaar, H ;
Boureau, F ;
Brochet, B ;
Bruxelle, J ;
Cunin, G ;
Fermanian, J ;
Ginies, P ;
Grun-Overdyking, A ;
Jafari-Schluep, H ;
Lantéri-Minet, M ;
Laurent, B ;
Mick, G ;
Serrie, A ;
Valade, D ;
Vicaut, E .
PAIN, 2005, 114 (1-2) :29-36
[6]
Development and validation of the neuropathic pain symptom inventory [J].
Bouhassira, D ;
Attal, N ;
Fermanian, J ;
Alchaar, H ;
Gautron, M ;
Masquelier, E ;
Rostaing, S ;
Lanteri-Minet, M ;
Collin, E ;
Grisart, J ;
Boureau, F .
PAIN, 2004, 108 (03) :248-257
[7]
Prevalence of chronic pain with neuropathic characteristics in the general population [J].
Bouhassira, Didier ;
Lanteri-Minet, Michel ;
Attal, Nadine ;
Laurent, Bernard ;
Touboul, Chantal .
PAIN, 2008, 136 (03) :380-387
[8]
Advances in neuropathic pain - Diagnosis, mechanisms, and treatment recommendations [J].
Dworkin, RH ;
Backonja, M ;
Rowbotham, MC ;
Allen, RR ;
Argoff, CR ;
Bennett, GJ ;
Bushnell, MC ;
Farrar, JT ;
Galer, BS ;
Haythornthwaite, JA ;
Hewitt, DJ ;
Loeser, JD ;
Max, MB ;
Saltarelli, M ;
Schmader, KE ;
Stein, C ;
Thompson, D ;
Turk, DC ;
Wallace, MS ;
Watkins, LR ;
Weinstein, SM .
ARCHIVES OF NEUROLOGY, 2003, 60 (11) :1524-1534
[9]
Patient self-reports in pharmacoeconomic studies - Their use and impact on study validity [J].
Evans, C ;
Crawford, B .
PHARMACOECONOMICS, 1999, 15 (03) :241-256
[10]
painDETECT:: a new screening questionnaire to identify neuropathic components in patients with back pain [J].
Freynhagen, Rainer ;
Baron, Ralf ;
Gockel, Ulrich ;
Toelle, Thomas R. .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) :1911-1920